# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeu...
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.
OncoCyte (NASDAQ:OCX) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.67) by ...
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and raises the price target from $3.6 to $4.25.
- SEC Filing
Stephens & Co. analyst Mason Carrico reiterates OncoCyte (NASDAQ:OCX) with a Equal-Weight and maintains $4 price target.